C35-CVZ
General
Type : Pyrimidine
Chemical_Nomenclature : 3-[(~{E})-5-[ethyl-[(2-nitrophenyl)methyl]amino]pent-1-enyl]-1-[5-[ethyl-[(2-nitrophenyl)methyl]amino]pentyl]-6-methyl-pyrimidine-2,4-dione
Canonical SMILES : CCN(CCCCCn1c(C)cc(=O)n(C=CCCCN(CC)Cc2ccccc2[N+]([O-])=O)c1=O)Cc1ccccc1[N+]([O-])=O
InChI : InChI=1S\/C33H44N6O6\/c1-4-34(25-28-16-8-10-18-30(28)38(42)43)20-12-6-14-22-36-27(3)24-32(40)37(33(36)41)23-15-7-13-21-35(5-2)26-29-17-9-11-19-31(29)39(44)45\/h8-11,15-19,23-24H,4-7,12-14,20-22,25-26H2,1-3H3\/b23-15+
InChIKey : WVBROKGEXVFXBW-HZHRSRAPSA-N
Other name(s) : C35,C-35,CVZ
MW : 620.74
Formula : C33H44N6O6
CAS_number :
PubChem : 137349134
UniChem : WVBROKGEXVFXBW-HZHRSRAPSA-N
IUPHAR :
Wikipedia :
Target
Families :
Stucture :
Protein :
References (1)
| Title : New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease - Zueva_2019_Neuropharmacol_155_131 |
| Author(s) : Zueva IV , Dias J , Lushchekina SV , Semenov VE , Mukhamedyarov MA , Pashirova TN , Babaev VM , Nachon F , Petrova N , Nurullin LF , Zakharova LY , Ilyin VI , Masson P , Petrov KA |
| Ref : Neuropharmacology , 155 :131 , 2019 |
| Abstract : Zueva_2019_Neuropharmacol_155_131 |
| ESTHER : Zueva_2019_Neuropharmacol_155_131 |
| PubMedSearch : Zueva_2019_Neuropharmacol_155_131 |
| PubMedID: 31132435 |
| Gene_locus related to this paper: human-ACHE |